Endpoint Exposure‐Response Analyses in the Presence of Concurrent Dose Modification During Clinical Trials
Clinical Pharmacology & Therapeutics · 2026-02 · 119 (2) · 546-554
DOI: 10.1002/cpt.70144 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 25.11.2025. Verfasst von Rui Zhong und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Azetidines, Clinical Trials as Topic, Endpoint Determination, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Exposure‐response (E‐R) analyses are essential for dose selection in drug development, yet conventional endpoint E‐R approaches often overlook concurrent clinical events such as adverse event (AE)‐driven dose modifications (DMs), potentially leading to biased or misleading conclusions. In this study, we developed a framework to quantify the impact of AE‐driven DMs on endpoint E‐R relationships and to explore strategies to improve their accuracy. Using duvelisib as an exemplar, a drug known for frequent DMs due to Grade ≥ 3 infections, pneumonia, or transaminase elevations, we evaluated E‐R relationships under three scenarios: ground truth, conventional E‐R (based on planned dose exposures), and DM‐adjusted E‐R (accounting for AE‐induced DMs and resultant exposure changes). Our analyses showed that conventional E‐R analyses often deviated substantially from the ground truth at frequent DMs, particularly for AEs with delayed onset. Early‐onset AEs and their resultant DMs could significantly distort E‐R relationships for subsequent AEs. DM‐adjusted E‐R analyses better approximate the ground truth, especially for late‐occurring AEs, but may introduce a risk of overcorrection of early‐occurring AEs. These findings highlight the critical need to incorporate the timing and nature of AEs into E‐R analyses to ensure robust interpretation, particularly in settings where DMs are frequent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Princeton, New Jersey, USA.
ORCID-Profile: Rui Zhong, Yanguang Cao
Förderung
- NIH HHS
- National Institutes of Health
Zitieren
APA
Zhong, R., & Cao, Y. (2026). Endpoint Exposure‐Response Analyses in the Presence of Concurrent Dose Modification During Clinical Trials. Clinical Pharmacology & Therapeutics, 119(2), 546-554. https://doi.org/10.1002/cpt.70144
Vancouver
Zhong R, Cao Y. Endpoint Exposure‐Response Analyses in the Presence of Concurrent Dose Modification During Clinical Trials. Clinical Pharmacology & Therapeutics. 2026;119(2):546-554. doi:10.1002/cpt.70144
BibTeX
@article{Zhong2026,
author = {Zhong, Rui and Cao, Yanguang},
title = {Endpoint Exposure‐Response Analyses in the Presence of Concurrent Dose Modification During Clinical Trials},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
volume = {119},
number = {2},
pages = {546--554},
doi = {10.1002/cpt.70144}
}
EUVIMED